| The influence of nicardipine in patients with high risk of stroke. | |
| | |
MedLine Citation:
|
PMID: 1369703 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Blood pressure and clinical status of 1,736 patients with cerebrovascular disease were observed during 12 months of treatment with nicardipine. The most common diagnoses were chronic cerebral ischemia (53.2%), transient ischemic attacks (TIA; 25.1%), and cerebral infarct (8.7%); 50.1% of patients were classed as hypertensive [systolic blood pressure (SBP) > or = 160 mm Hg or diastolic blood pressure (DBP) > or = 90 mm Hg]. Most patients (91.2%) received a daily dose of 60 mg nicardipine. Additional treatments included diuretics (37%), beta-blockers (11.5%), other antihypertensive drugs (15.8%), platelet antiaggregants (25.1%), and cardiotonic drugs (15.1%). A total of 282 patients (16.2%) were lost to follow-up, 21 (1.2%) patients withdrew due to side effects, 32 (1.8%) died, and 9 (0.5%) patients had treatment interrupted due to concomitant illness. In the hypertensive subgroup, blood pressure (SBP/DBP) was reduced from a mean baseline value of 175 +/- 22/97 +/- 14 mm Hg to 152 +/- 17/85 +/- 11 mm Hg at 3 months and 149 +/- 23/81 +/- 11 mm Hg after 12 months of treatment. The incidence of TIA or stroke among these patients was reduced from 29 cases (3.5%) during the first 3 months to 11 cases (1.54%) during months 4-12 (p < 0.01). In normotensive patients there were 18 (2.15%) cases during months 1-3 and 13 (1.55%) cases during months 4-12 (difference not significant). In the 280 patients treated with nicardipine alone, the most frequent side effects during the first month were facial flushing (6.8%), gastrointestinal problems (5%), dizziness (3.2%), headache (3.2%), drowsiness (3.2%), and hypotension (1.1%). Most of these side effects were transient.(ABSTRACT TRUNCATED AT 250 WORDS) |
| | |
Authors:
|
M Ribas Mundó; R Lozano |
Related Documents
:
|
7433343 - Long-term treatment of hypertension with labetalol. 1860093 - Converting enzyme inhibition attenuates the noradrenaline response to the valsalva mane... 23192403 - The influence of obesity on the outcome of treatment of lumbar disc herniation: analysi... |
Publication Detail:
|
Type: Clinical Trial; Controlled Clinical Trial; Journal Article; Multicenter Study |
Journal Detail:
|
Title: Journal of cardiovascular pharmacology Volume: 16 Suppl 2 ISSN: 0160-2446 ISO Abbreviation: J. Cardiovasc. Pharmacol. Publication Date: 1990 |
Date Detail:
|
Created Date: 1995-08-17 Completed Date: 1995-08-17 Revised Date: 2004-11-17 |
Medline Journal Info:
|
Nlm Unique ID: 7902492 Medline TA: J Cardiovasc Pharmacol Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: S16-9 Citation Subset: IM |
Affiliation:
|
University Hospital Germas Trias i Pujol, Badalona, Barcelona, Spain. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Aged, 80 and over Cerebrovascular Disorders / etiology, prevention & control* Disease Susceptibility Female Humans Male Middle Aged Nicardipine / therapeutic use* Risk Factors |
| Chemical | |
Reg. No./Substance:
|
55985-32-5/Nicardipine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Clinical effects of calcium antagonists in hypertensive diabetics.
Next Document: The influence of nicardipine on left ventricular hemodynamics and compliance in patients with corona...